TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00936338

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: splint and joint mobilization self exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: splint and joint mobilization self exercise
Study: NCT00206960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zuclopenthixol
Description: Patients will be administered zuclopenthixol orally in doses between 4 -24 mg/day, depending on an effective reduction of symptoms
Study: NCT03899090

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Float chair
Description: Subject floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
Study: NCT03853837

Intervention type: DIAGNOSTIC_TEST
Intervention: rest-exercise echocardiography
Description: an echocardiogram performed during rest and exercise
Study: NCT04144764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workplace-based exercise
Description: Participants will have to perform 10-week of workplace-based exercise programme which consist of 5 sessions of 10 minutes per week. The workplace-based exercise programme will consist of general stretching and strengthening exercise using resistance tubing for both the neck and upper limb. Specific rotator cuff and scapular muscles strengthening exercise were also included to enhance glenohumeral and scapular kinematics (Appendix). Each participant will receive a set of elastic resistance tubing that comprise red (2kg), green (3kg) and blue (4kg). The exercise programme will be taught by physiotherapist during their baseline assessment. They will be asked to train at the workplace during workdays (Monday to Friday), five times a week during the 10-week intervention. The program built on the principle of progressive overload.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ergonomic advice and education
Description: Participants will receive ergonomic training and education on how to adjust their workstations to reduce the ergonomic risk factors when using computers.
Study: NCT00890318

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-072
Description: Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-072
Description: Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-072
Description: Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.

Intervention type: OTHER
Group type: OTHER
Intervention: ketoconazole
Description: Tablet, see Arm Description for intervention information.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.
Study: NCT02546141

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: skimmed milk (UHT)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: skimmed milk (pasteurized)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: skimmed yoghurt

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: full-fat milk (UHT)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-homogenized full-fat milk (pasteurized)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: full-fat cheese (semi-matured)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whey protein

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: micellar casein
Study: NCT00907114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac tromethamine
Description: Presentation 5 mg/ml; Dosage: one drop (0.25 mg) four times a day during one week after panphotocoagulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polivynilic alcohol
Description: Presentation: alcohol polivinilico 14 mg/ml; Dosage: one drop (0.7 mg alcohol polivinilico) four times a day during one week after panphotocoagulation
Study: NCT05252975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Setup and Imaging for at CT radiation planning
Description: Patients will undergo an additional CT scan acquisition at CT radiotherapy planning in order that all participating patients have a prone and supine CT scan available to compare radiation therapy plans.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Setup and Imaging for at CT radiation planning
Description: Patients will undergo an additional CT scan acquisition at CT radiotherapy planning in order that all participating patients have a prone and supine CT scan available to compare radiation therapy plans.
Study: NCT01106950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cells
Description: Given by infusion on Day 0. The product is T cell-depleted (CD3-) and B cell-depleted (CD19). Target dose for infusion is \< or = 8 x 10\^7 nucleated cells/kilogram.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered as a 1 hour intravenous infusion once a day for 5 doses beginning on day -6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered as a 2 hour intravenous infusion with high volume fluid flush and mesna per institutional guidelines on day -5 and -4 one hour after fludarabine infusion. (Day -4 administration may be omitted if patient has had a transplant in the previous 4 months.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox
Description: 12 ug/kg/day will be administered on day -1 and day -2 intravenously.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor lymphapheresis
Description: Day -1 before planned NK cell infusion, the donor will undergo lymphapheresis (Removal of lymphocytes from donated blood, with the remainder of the blood retransfused into the donor).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Administered after NK cell infusion, 10 million units every other day for a total of 6 doses. (Patients weighing less than 45 kilograms will receive a dose of 5 million units/m\^2 every other day for 6 doses).
Study: NCT02825459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstinence from e-cigarettes
Description: Abrupt cessation for 6 days
Study: NCT00558883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acarbose
Description: oral application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acarbose
Description: oral application
Study: NCT03105401

Intervention type: OTHER
Intervention: Assessment of hallucinations in Parkinson's disease
Description: Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.
Study: NCT02468700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Study: NCT02082288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Edessy ICSI Outcome Embryo Score
Description: EIOS:~Age (ys) \>35 (0) 30-35 (1) \<30 (2) No of retrived oocyte \<5 (0) 5-9 (1) ≥ 10 (2) No of EC embryos \<2 (0) 2-4 (1) \>4 (2) No of good quality embryos \<3 (0) 3-5 (1) \>5 (2) No of embryos transferred -------- (0) ≤2 (1) \>2 (2)
Study: NCT03967327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patches
Description: It should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest. The skin should be relatively hairless. If none are available, the hair at the site should be clipped, not shaven.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine transdermal patches
Description: It should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest. The skin should be relatively hairless. If none are available, the hair at the site should be clipped, not shaven.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate Sustained-Release Tablet
Description: It will be administered orally twice (q12h) daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate Sustained-Release Tablet
Description: It will be administered orally twice (q12h) daily.
Study: NCT02123875

Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: Control arm
Description: Routine hospital based physiotherapy
Study: NCT01410253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of four techniques of physiotherapy
Description: The patients receive conventional physiotherapy, expiratory positive airway pressure, inspiratory muscle training and physical exercise. Twice daily for seven days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of three techniques of physiotherapy
Description: Patients receive conventional physiotherapy, expiratory positive airway pressure and physical exercise. Twice daily for seven days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of two techniques of physiotherapy
Description: Patients receive conventional physiotherapy,expiratory positive airway pressure respiratory muscle training. Twice daily for seven days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard therapy
Description: Patients receive conventional physiotherapy and expiratory positive airway pressure. Twice daily for seven days
Study: NCT00669344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exelon (rivastigmine)
Description: Capsules, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
Study: NCT05625464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCTP
Description: Real-time automated monitoring of the electronic medical record to identify suspected sepsis patients without completion of sepsis bundle measures within 1-hour of the completion deadline and generated reminder pages. Clinicians responsible for patients randomized to the intervention receive reminder pages whereas no pages are sent for control arm patients.
Study: NCT00143572

Intervention type: DRUG
Group type: OTHER
Intervention: Magnesium Pidolate, Hydroxyurea
Description: Intervention Description: Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months. Mg pidolate will be given at an initial dose of 0.6 mEq/kg/day divided into 2 daily doses for the first cohort of patients. This dose will be escalated for the subsequent patient cohorts as defined by a classic Phase I design (according to toxicity).
Study: NCT05562921

Intervention type: BEHAVIORAL
Intervention: Controls-ususal care
Description: Controls: patients who did not receive remote patient monitoring for blood pressure prescribed during routine care delivery, with multivariable matching to cases

Intervention type: BEHAVIORAL
Intervention: Cases-remote patient monitoring prescribed
Description: Cases: patients prescribed remote patient monitoring for blood pressure during routing care delivery
Study: NCT00238290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab + Letrozole
Description: Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
Study: NCT02838238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03355456

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Ablation procedure to eliminate atrial fibrillation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Ablation procedure to eliminate atrial fibrillation
Study: NCT00610519

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: mixture of aromatic essential oils.
Description: 3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the throat.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0:1% of Lemon VIP (Florasynth,Israel), spraying to the throat.
Study: NCT00002874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: One (150 mg) tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 64.8 Gy in 36 fractions (1.8 Gy in 5 daily sessions per week) to the original prostate volume, the tumor resection bed, and the proximal membranous urethra.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiation therapy
Description: 64.8 Gy in 36 fractions (1.8 Gy in 5 daily sessions per week) to the original prostate volume, the tumor resection bed, and the proximal membranous urethra.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: One tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
Study: NCT02530242

Intervention type: DEVICE
Group type: OTHER
Intervention: End-tidal Carbon Monoxide Subjects
Description: ETCO monitor will be used to measure CO levels in subjects and controls.

Intervention type: DEVICE
Group type: OTHER
Intervention: End-tidal Carbon Monoxide Controls
Description: ETCO monitor will be used to measure CO levels in subjects and controls.
Study: NCT02195323

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous injection
Description: Intravenous injection of bone marrow derived MSC in patients with CKD.
Study: NCT00136474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amifostine
Description: Given 30-60 minutes prior to daily radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Daily radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Daily radiation therapy
Study: NCT00839826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: 2,5 mg bid,5 mg bid,10mg bid, 20 mg bid, 20 mg tid, 30 mg bid, dose escalation trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 40 mg bid
Study: NCT02624089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivicaine will be administered via in-line nebulization using the Aeroneb Pro™ system

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be administered via in-line nebulization using the Aeroneb Pro™ system
Study: NCT02416141

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fast release oro dispersible tramadol 50 mg
Description: idem arm 1
Study: NCT02233088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ELM Group
Description: ELM participants are trained to portion their meals according to the Perfect Plate method, a modified version of the USDA's ChooseMyPlate.gov. The stress management focuses on mindful living, cognitive restructuring; the enhancement of positive emotions. The physical activity component focuses on reduction of sedentary activity (by increasing daily step counts) and moderate-to-vigorous physical activity.

Intervention type: OTHER
Group type: OTHER
Intervention: ELM Classes
Description: ELM classes will be administered through Rush Generations program and focus on health education.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ELM Individual
Description: ELM Individual arm participants will receive education materials on metabolic syndrome and diet, exercise, stress reduction recommendations. The participants will be recommended to follow these guidelines and discuss/seek support from their health care provider (visits at baseline, 3 and 6 months will be recommended.
Study: NCT04441398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Subjects will receive nitazonanide 600 mg TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
Study: NCT00665639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micafungin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micafungin
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caspofungin
Description: IV
Study: NCT04042428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin injection
Description: Subjects receive a daily subcutaneous dose of 0.2 IU/kg (0.067 mg/kg) of recombinant somatropin (rhGH) during 14 days.
Study: NCT03251105

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: supraglottic airway intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: supraglottic airway intubation
Study: NCT03265392

Intervention type: OTHER
Group type: OTHER
Intervention: Bread
Description: Serving of wheat bread providing 50 g of carbohydrates

Intervention type: OTHER
Group type: OTHER
Intervention: Bread
Description: Serving of wheat bread providing 50 g of carbohydrates

Intervention type: OTHER
Group type: OTHER
Intervention: Bread
Description: Serving of wheat bread providing 50 g of carbohydrates

Intervention type: OTHER
Group type: OTHER
Intervention: Bread
Description: Serving of wheat bread providing 50 g of carbohydrates

Intervention type: OTHER
Group type: OTHER
Intervention: Water
Description: 250 mL of water

Intervention type: OTHER
Group type: OTHER
Intervention: Water
Description: 250 mL of water

Intervention type: OTHER
Group type: OTHER
Intervention: Lemon juice
Description: 250 mL of lemon juice
Study: NCT04453150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternate-day fasting
Description: Alternate-day fasting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Ketogenic diet
Study: NCT05283733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reverse conversion technique
Description: converting open appendectomy to laparoscopic technique for proper control of intraabdominal sepsis
Study: NCT04549987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space closure without changing working archwire monthly
Description: Upper premolar space closure using the same 0.019X0.025 stainless steel archwire every month
Study: NCT01483651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: The first dose of glucagon will be delivered approximately one hour after infusion of IV insulin has started. The subsequent three doses will be delivered every two hours. The dosage will depend on the IV insulin infusion (50 units regular insulin in 499.5 mL 0.9% saline): Study 1) insulin 0.01 units/kg/hour and glucagon doses (ug): 10,25,45,70; Study 2) insulin 0.02 units/kg/hr and glucagon doses (ug): 25,45,70,100; Study 3) insulin 0.04 units/kg/hr and glucagon doses (ug): 45,70,100,135; Study 4) insulin 0.08 units/kg/hr and glucagon doses (ug): 70,100,135,175. Insulin levels and glucagon doses will be randomized. Glucagon will be reconstituted with 10 mL of sterile water and administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin was administered at a low, medium or high infusion rate. The intervention sequence was randomly pre-determined for all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin was administered at a low, medium or high infusion rate. The intervention sequence was randomly pre-determined for all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin was administered at a low, medium or high infusion rate. The intervention sequence was randomly pre-determined for all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin was administered at a low, medium or high infusion rate. The intervention sequence was randomly pre-determined for all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin was administered at a low, medium or high infusion rate. The intervention sequence was randomly pre-determined for all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin was administered at a low, medium or high infusion rate. The intervention sequence was randomly pre-determined for all participants.
Study: NCT06522802

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: balance tests, reaction time evaluation
Description: Only 3 tests were applied to participants
Study: NCT04483037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bowklean
Description: assigned intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bowklean
Description: assigned intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bowklean
Description: assigned intervention
Study: NCT03265392

Intervention type: OTHER
Group type: OTHER
Intervention: Lemon juice
Description: 250 mL of lemon juice

Intervention type: OTHER
Group type: OTHER
Intervention: Tea
Description: 250 mL of tea

Intervention type: OTHER
Group type: OTHER
Intervention: Tea
Description: 250 mL of tea

Intervention type: OTHER
Group type: OTHER
Intervention: Peas
Description: 20 peas

Intervention type: OTHER
Group type: OTHER
Intervention: Peas
Description: 20 peas

Intervention type: OTHER
Group type: OTHER
Intervention: Peas
Description: 20 peas
Study: NCT01563822

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Follicular fluid
Description: The intervention is flushing the uterine cavity with 2 ml of clear follicular fluid surrounding mature oocytes after ovum pick-up through an IUI catheter